Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis
| Autor: | Pier Luigi Meroni, Gian Domenico Sebastiani, Paolo Airò, Mirko Scarsi, Valeria Caneparo, Valeria Riccieri, Santo Landolfo, Renato Alberto Sinico, Marisa Gariglio, Roberto Gerli, Silvia Costa, Angela Tincani, Milvia Lotzniker, Gabriella Morozzi, Antonella Afeltra, Paola Faggioli, Antonella Radice, Francesca Bellisai, Michele Mondini |
|---|---|
| Přispěvatelé: | Costa, S, Mondini, M, Caneparo, V, Afeltra, A, Airò, P, Bellisai, F, Faggioli, P, Gerli, R, Lotzniker, M, Meroni, P, Morozzi, G, Radice, A, Riccieri, V, Scarsi, M, Sebastiani, G, Sinico, R, Tincani, A, Gariglio, M, Landolfo, S |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
Systemic disease Autoantibodies Diagnosis IFI16 Interferon Systemic sclerosis Serology Systemic sclerosi Immunopathology Diagnosis Medicine Pharmacology (medical) skin and connective tissue diseases Nuclear Protein education.field_of_study integumentary system biology Nuclear Proteins Middle Aged Autoantibodie Connective tissue disease Antibodies Anti-Idiotypic RNA Bacterial DNA Topoisomerases Type I Phosphoprotein Antibodies Antinuclear Interferon Systemic sclerosis Female Antibody Case-Control Studie Diagnosi Human Population Enzyme-Linked Immunosorbent Assay Rheumatology Humans Clinical significance IFI16 education Autoantibodies Aged Scleroderma Systemic business.industry autoantibodies diagnosis ifi16 interferon systemic sclerosis Autoantibody Biomarker medicine.disease Phosphoproteins Case-Control Studies Immunology biology.protein business Biomarkers |
| Popis: | Objectives: To validate the clinical significance of anti-IFI16 autoantibodies in SSc and assess their associations with serological markers of SSc. Methods: A semi-quantitative ELISA was used to detect anti-IFI16 autoantibodies in the sera of 344 SSc patients from seven Italian hospitals and 144 healthy controls. SSc-associated autoantibodies [anti-RNA polymerase III (anti-RNAP III) antibodies, anti-centromere, anti-topo I] and IF patterns were evaluated using commercial assays. Statistical analyses were performed to test clinical and serological associations. Results: The results of this study confirm a significant prevalence (29%) of anti-IFI16 antibodies in the SSc population (n = 344). Anti-IFI16 antibodies were also detected in 30% of the SSc patients who tested negative for both ACAs and anti-topo I (anti-Scl70) antibodies. In this subgroup of patients, anti-IFI16 antibodies were significantly associated with the limited cutaneous form of SSc with a sensitivity of 40% and a specificity of 81%. Moreover, analysis of the distribution of anti-RNAP III antibodies vs anti-IFI16 in the same SSc population showed that they were mutually exclusive. IIF revealed no association between anti-IFI16 and fluoroscopic patterns, due to a lack of IFI16 autoantigen in HEp-2 cells. Anti-IFI16 antibody levels were also significantly associated with heart involvement. Conclusions: Anti-IFI16 autoantibodies are frequently detected in SSc, displaying clinical and laboratory associations, and being particularly useful for diagnosis and disease classification in patients who are negative for other SSc serological markers. © The Author 2010. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|